Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H15ClNO4.Na |
Molecular Weight | 379.769 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC([O-])=O
InChI
InChIKey=JMHRGKDWGWORNU-UHFFFAOYSA-M
InChI=1S/C19H16ClNO4.Na/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12;/h3-9H,10H2,1-2H3,(H,22,23);/q;+1/p-1
Molecular Formula | C19H15ClNO4 |
Molecular Weight | 356.78 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11906281 |
3.0 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20503989 |
10.0 nM [IC50] | ||
Target ID: CHEMBL4681 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23432095 |
100.0 nM [IC50] | ||
Target ID: CHEMBL1835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2547071 |
100.0 nM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
|||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2369 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2 μg/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7762 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.22 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting Sources: Page: p.152Nausea (mild) Anorexia (mild) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 11 patient) Sources: Pruritus (below serious, 5 patients) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 34 patients) Sources: Vomiting (below serious, 11 patient) Constipation (below serious, 8 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Deep vein thrombosis, Headache... Other AEs: Deep vein thrombosis (serious, 1 patient) Sources: Headache (below serious, 13 patients) Pruritus (below serious, 1 patient) Presyncope (below serious, 5 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 36 patients) Sources: Vomiting (below serious, 12 patients) Constipation (below serious, 7 patients) Post procedural haemorrhage (below serious, 7 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 12 patients) Sources: Pruritus (below serious, 3 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Other AEs: Headache, Vomiting... Other AEs: Headache (below serious, 17 patients) Sources: Vomiting (below serious, 9 patients) |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (serious) Sources: Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (serious) Bleeding (grade 3-5) Ulceration (grade 3-5) Perforation stomach (grade 3-5) Perforation of intestine (grade 3-5) |
0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Other AEs: Gingival bleeding, Application site pruritus... Other AEs: Gingival bleeding (below serious, 1 patient) Sources: Application site pruritus (below serious, 1 patient) Inflammation (below serious, 1 patient) Nasopharyngitis (below serious, 1 patient) Ligament sprain (below serious, 1 patient) Rash (below serious, 2 patients) Drug eruption (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | Disc. AE | 0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Anorexia | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Nausea | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Headache | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Pruritus | below serious, 5 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Nausea | below serious, 34 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Constipation | below serious, 8 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Pruritus | below serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Headache | below serious, 13 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Presyncope | below serious, 5 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Deep vein thrombosis | serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 12 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Nausea | below serious, 36 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Constipation | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Post procedural haemorrhage | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 12 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Pruritus | below serious, 3 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 17 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Vomiting | below serious, 9 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Bleeding | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Myocardial infarction | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation of intestine | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation stomach | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Stroke | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Ulceration | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Cardiac thrombosis | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Gastrointestinal disorder NOS | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Application site pruritus | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Drug eruption | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Gingival bleeding | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Inflammation | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Ligament sprain | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Nasopharyngitis | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Rash | below serious, 2 patients | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Aspirin sensitivity: other drugs. | 1975 Feb |
|
[Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis]. | 1975 Feb |
|
[Intrahepatic cholestasis following treatment with penicillamine D and indomethacine]. | 1976 May 28 |
|
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem. | 1979 Sep 15 |
|
Persistent pulmonary hypertension after maternal naproxen ingestion in a term newborn: a case report. | 2000 |
|
[Effect of carrageenan and indomethacin on the growth of a murine fibrosarcoma]. | 2000 |
|
Matrix metalloproteinases 2 and 9 in indomethacin-induced rat gastric ulcer. | 2000 |
|
The role of nitric oxide and prostaglandin E2 on the hyperalgesia induced by excitatory amino acids in rats. | 2000 Apr |
|
Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action? | 2000 Aug |
|
Chronic intrathecal cannulation enhances nociceptive responses in rats. | 2000 Aug |
|
Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. | 2000 Dec |
|
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. | 2000 Dec 8 |
|
Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. | 2000 Jul |
|
Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus. | 2000 Jul |
|
Ibuprofen as effective as indomethacin for patent ductus arteriosus. | 2000 Jul 25 |
|
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. | 2000 Jul-Aug |
|
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors. | 2000 Jun |
|
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. | 2000 Jun 15 |
|
Effects of hydrogen peroxide scavenger Catalase on villous microcirculation in the rat small intestine in a model of inflammatory bowel disease. | 2000 May |
|
Role of endothelin-converting enzyme-1 in the suppression of constitutive nitric oxide synthase in rat gastric mucosal injury by indomethacin. | 2000 Nov |
|
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. | 2000 Nov |
|
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. | 2000 Nov |
|
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells. | 2000 Nov 17 |
|
Role of BAX in the apoptotic response to anticancer agents. | 2000 Nov 3 |
|
Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases. | 2000 Nov-Dec |
|
A case of living-related kidney transplantation in Bartter's syndrome. | 2000 Oct |
|
Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. | 2000 Sep |
|
Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice. | 2000 Sep 1 |
|
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. | 2000 Sep 7 |
|
Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. | 2000 Sep 8 |
|
Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. | 2001 |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocyte: lack of contribution to loss of cartilage anabolism. | 2001 Apr 15 |
|
Indomethacin increases 15-PGDH mRNA expression in HL60 cells differentiated by PMA. | 2001 Feb |
|
Does exposure to magnesium sulfate in utero decrease the risk of necrotizing enterocolitis in premature infants? | 2001 Feb |
|
Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. | 2001 Feb |
|
Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. | 2001 Feb |
|
Increased 15-HPETE production decreases prostacyclin synthase activity during oxidant stress in aortic endothelial cells. | 2001 Feb 1 |
|
An investigation into the thermal behaviour of an amorphous drug using low frequency dielectric spectroscopy and modulated temperature differential scanning calorimetry. | 2001 Jan |
|
Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. | 2001 Jan |
|
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | 2001 Jan |
|
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. | 2001 Jan 5 |
|
Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. | 2001 Mar |
|
Effect of indomethacin on gallbladder inflammation and contractility during acute cholecystitis. | 2001 Mar |
|
Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. | 2001 Mar |
|
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. | 2001 Mar 1 |
|
Inactivation of creatine kinase during the interaction of indomethacin with horseradish peroxidase and hydrogen peroxide: involvement of indomethacin radicals. | 2001 Mar 14 |
|
Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production. | 2001 Mar 9 |
|
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. | 2001 Mar 9 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27988363
U251 cells were incubated for 24 h with different concentrations of indomethacin (0.03, 0.06, 0.13, 0.25, 0.5, 1 mkM), diclofenac (DIC),naproxen (NAP), or ketoprofen (KET), and the cell viability was assessed by MTT or crystal violet (CV) tests.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 00:30:42 GMT 2023
by
admin
on
Sat Dec 16 00:30:42 GMT 2023
|
Record UNII |
1C9D998830
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID20227631
Created by
admin on Sat Dec 16 00:30:42 GMT 2023 , Edited by admin on Sat Dec 16 00:30:42 GMT 2023
|
PRIMARY | |||
|
1C9D998830
Created by
admin on Sat Dec 16 00:30:42 GMT 2023 , Edited by admin on Sat Dec 16 00:30:42 GMT 2023
|
PRIMARY | |||
|
23675763
Created by
admin on Sat Dec 16 00:30:42 GMT 2023 , Edited by admin on Sat Dec 16 00:30:42 GMT 2023
|
PRIMARY | |||
|
231-670-4
Created by
admin on Sat Dec 16 00:30:42 GMT 2023 , Edited by admin on Sat Dec 16 00:30:42 GMT 2023
|
PRIMARY | |||
|
7681-54-1
Created by
admin on Sat Dec 16 00:30:42 GMT 2023 , Edited by admin on Sat Dec 16 00:30:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|